(IQR): 9.6 (6–18.3)], with less than a quarter on biologic psoriasis therapy for skin disease management (n = 13 (anti-TNFα n = 10, anti-IL17 n = 2, anti-IL12/23 n = 1)) at baseline (Table 1). This evidence concerns the gene IL17A and psoriasis.